POLRMT

Across TCGA pan-cancer cohorts, POLRMT Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated POLRMT data layer compared with 21 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher POLRMT Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated POLRMT expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

LIHC, LGG, and BLCA are the cancer types where POLRMT Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.059	0.777	<.001	36	view →
LGG	OS	Median	All	0.208	0.896	<.001	12	view →
BLCA	OS	Median	II,III,IV	1.000	0.410	.023	12	view →
UCEC	DFS	Median	All	0.965	0.626	.019	8	view →
SARC	DFS	Median	All	0.182	0.612	.026	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
STAD	OS	Median	III,IV	0.196	0.628	.036	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

POLRMT–LIHC (OS)

Open the LIHC breakdown →